It is not possible to titrate the dose to the plasma concentration of Anavex 2-73 during a double or triple blind trial, HOWEVER after the trial is completed treatment can be continued and the all subjects in the trial including those previously on placebo can all have trier dose titrated to a level that increase their individual plasma level of Anavex 2-73 to at least 4 ng/ml.
Imagine the results where those not responding during the trial all responding after the trial on optimized dosing of Anavex 2-73.
Titration related to each subjects size, weight and metabolism could increase the response and efficacy of Anavex 2-73.
See pages 12 and 13.
A plasma concentration of greater than 4 ng/ml would increase postive responses and efficacy to Anavex 2-73
Market Data 
Markets 
